Posters

Prevalence and interrelated factors of cataract development in the Russian population

Poster Details

First Author: G.Israfilova RUSSIA

Co Author(s):    M. Bikbov   R. Zainullin                 

Abstract Details

Purpose:

To assess the prevalence and interrelated factors of cataract development in the Russian population.

Setting:

"Ufa Eye and Medical Study" (UEMS).

Methods:

As part of the UEMS examinations of the people over 40 years old living in Ufa and districts was conducted. Cataract was diagnosed based on photographs of the anterior segment of the eye according to the AREDS classification (2005). The morphological changes of the optic disc (OD) were assessed using images taken with the Visucam 500 (Carl Zeiss, Germany). The study involved 5899 people, averaged age - 59.0±10.7. Population by place of residence: 2499 (42.4%) inhabitants of the city and 3400 (57.6%) people living in the rural region. The gender distribution - 3319 (56.3%) women and 2580 (43.7%) men.

Results:

The nuclear cataract was detected in 86.6% of people (95% CI: 2,14 2,19), cortical-12,7% (95% CI: 0.12 0.14), subcapsular-0.6% (95% CI: 0,004 0,008). Multivariate regression analysis revealed a relationship between menopause and nuclear cataract development (p<0.001, odds ratio (OR): 1.99; 95% CI: 1,01 3,96).  Cataract prevalence among urban residents is higher (p<0.001, 95% CI: 0,05 0,37). The prevalence of cataracts was not associated with cardiovascular disease, hypertension, and biochemical blood parameters. The OD lesion was diagnosed in 291 (4.9%). Multivariate regression analysis revealed the relationship between OD lesion and cataract progression (p<0.001, OR: 1,440, 95% CI: 1,26-1,65).

Conclusions:

Conducting UEMS among the typical, ethnically mixed, urban and rural population of Russia over the age of 40 showed that the prevalence of nuclear cataract is 86.6% (95% CI: 2.14 2.19) and is associated with risk factors such as age, urban residence, development of menopause in women, the presence of glaucomatous lesions of OD.

Financial Disclosure:

... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented